All enrolled sufferers who acquired no less than just one dose of zosuquidar or placebo during induction were monitored with the event of adverse occasions (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse events ended up relevant to the period of extended and major myelosuppression as https://prim-o-glucosylcimifugin00986.dsiblogger.com/60873380/helping-the-others-realize-the-advantages-of-3